Scarica l'app Stockscreener
2.58
6.18%
-0.17
Pre-mercato:
2.58
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Editas Medicine Inc Borsa (EDIT) Ultime notizie
Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME) - Seeking Alpha
EDIT Upgraded by Guggenheim -- Rating Changed to Buy - GuruFocus
Editas Medicine (EDIT) Short Interest & Short Float | Updated Sep 2026 $EDIT - MarketBeat
EDIT Looks 34.1% Overvalued on GF Value™ Amid Gene Editing Secto - GuruFocus
EDIT Looks 40.5% Overvalued on GF Value™ - GuruFocus
Editas stock raised to Buy at Guggenheim (EDIT:NASDAQ) - Seeking Alpha
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday - Benzinga
This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Why is Editas Medicine stock rallying today? By Investing.com - Investing.com Canada
Guggenheim upgrades Editas Medicine to Buy, sets $5 price target - TradingView
Guggenheim upgrades Editas Medicine stock rating on gene editing therapy By Investing.com - Investing.com Canada
Guggenheim Upgrades Editas Medicine to Buy From Neutral, Price Target is $5 - Yahoo Finance
Guggenheim Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $5 - Moomoo
Editas Medicine, Inc.(NasdaqGS: EDIT) added to S&P Biotechnology Select Industry Index - marketscreener.com
Editas Medicine stock gains on gene-editing optimism and analyst support - AD HOC NEWS
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy - Yahoo Finance
Opaleye Management Inc. Buys 1,934,933 Shares of Editas Medicine, Inc. $EDIT - MarketBeat
EDIT: EDIT-401 targets up to 90% LDL reduction, with first patient dosing on track for this year - TradingView
Editas Medicine at Cantor conference: in vivo CRISPR push advances - Investing.com
Editas Medicine (NASDAQ: EDIT) Grants 950,000 Derivative Securities to CMO Ory Daniel Scott on September 8, 2026 - Kalkine Media
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Editas Medicine (NASDAQ: EDIT) awards options vesting through 2030 to its CMO - Stock Titan
Editas Medicine (NASDAQ: EDIT) CMO named as reporting insider - Stock Titan
Editas Medicine grants stock options to new chief medical officer - investing.com
Editas Medicine grants stock options to new chief medical officer By Investing.com - Investing.com Australia
New medical chief can earn the right to buy 950,000 Editas shares - Stock Titan
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 - MarketBeat
Editas Medicine, Inc. SEC Filing (Sep 9, 2026) - Stock Titan
Editas Medicine names Dan Ory as chief medical officer By Investing.com - Investing.com South Africa
EDIT: EDIT-401 aims for unprecedented LDL reduction, with first human data expected in 2027 - TradingView
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR By Investing.com - Investing.com India
Editas Medicine at Wells Fargo conference: a focused bet on CRISPR - Investing.com
Editas Medicine CFO Parison Amy Retains 13,839 Shares After Selling 453 at $3.04 Each - Kalkine Media
Editas Medicine Appoints Dan Ory as Chief Medical Officer - citybiz
A potential gene-editing treatment moves toward trials as Editas adds a veteran with more than 25 years' experience. - Stock Titan
Editas Medicine names Dan Ory as chief medical officer - Investing.com
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer - GlobeNewswire Inc.
Seven Fleet Capital Management LP Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Editas Medicine CSO Linda Burkly Sells 709 Shares to Cover RSU Tax Withholding - Kalkine Media
Editas Medicine CFO Amy Parison Sells Shares in September 2026 Under Pre-Set Plan - Kalkine Media
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,124 Shares of Stock - MarketBeat
Editas Medicine CEO Gilmore Neil O'Neill Sells 5,124 Shares to Cover Tax Withholding on RSU Vesting - Kalkine Media
Editas Medicine (EDIT) CSO stock sale follows tax plan - Stock Titan
Pre-set plan triggers Editas (NASDAQ: EDIT) CFO share sale - stocktitan.net
Editas Medicine (NASDAQ: EDIT) CEO sells 5,124 shares in tax-plan trade - Stock Titan
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Editas Medicine Inc. (EDIT) Peer Comparison – Compare with Others - Value Research
Editas Medicine (EDIT) Slides 1.3% to $3.04 as Support Level Comes into FocusRetracement Entry - vinanet.vn
EditasSlow Progress Doesn't Mean No Progress For In-Vivo Gene Editor (NASDAQ:EDIT) - Seeking Alpha
BlackRock Inc. Takes Position in Editas Medicine, Inc. $EDIT - MarketBeat
Boston and New York will host Editas Medicine talks this month - stocktitan.net
Editas Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Editas Medicine Files $400 Million Mixed Shelf - marketscreener.com
O'Neill plans another Editas (NASDAQ: EDIT) sale after June share trade - Stock Titan
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):